Mizuho lowered the firm’s price target on uniQure to $7 from $10 and keeps a Neutral rating on the shares. A key update from the Q4 report is that management expects to advance AMT-130 for Huntington’s disease into Phase 3 trials only after securing a collaboration partner, the analyst tells investors in a research note. The firm cites the absence of impactful near-term catalysts and partnership clarity for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QURE:
- uniQure price target lowered to $25 from $30 at H.C. Wainwright
- Snowflake downgraded and upgraded: Wall Street’s top analyst calls
- Goldman downgrades uniQure on uncertain path in Huntington’s
- uniQure downgraded to Neutral from Buy at Goldman Sachs
- A New Cause for Concern: uniQure N.V. Adds a New Innovation / R&D Risk